Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.70 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.70 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | LAP3 | P28838 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levamfetamine SCHEMBL1320449 | 1.00 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL6251824 | 1.00 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL31637552 | 1.00 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL8505954 | 0.93 | TAAR1 (0.61) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Mucic Acid SCHEMBL578987 | 0.93 | TAAR1 (0.66) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Mucic Acid SCHEMBL28326693 | 0.93 | TAAR1 (0.66) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Mucic Acid SCHEMBL578988 | 0.93 | TAAR1 (0.66) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Amphetamine SCHEMBL29127738 | 0.89 | TAAR1 (0.76) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Amphetamine SCHEMBL157108 | 0.86 | TAAR1 (0.79) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Amphetamine SCHEMBL8589685 | 0.86 | TAAR1 (0.79) | TAAR1SLC6A4SLC6A2MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717452-B1 | PROCESS FOR PREPARING ACYLATED AMPHETAMINE DERIVATIVES | SpecGx LLC (US) | 2024-06-05 | — | — | EP | claimed |
| EP-3717452-A1 | PROCESS FOR PREPARING ACYLATED AMPHETAMINE DERIVATIVES | SpecGx LLC (US) | 2020-10-07 | — | — | EP | claimed |
| CN-101426496-A | Use of cholesterol lowering agents and/or H3Treatment of non-alcoholic fatty liver disease with receptor antagonists/inverse agonists | SCHERING CORP (US) | 2009-05-06 | — | — | CN | claimed |
| US-20250368601-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE | VERANOVA L P (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| EP-3717452-B1 | PROCESS FOR PREPARING ACYLATED AMPHETAMINE DERIVATIVES | SpecGx LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024089666-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE | MACFARLAN SMITH LIMITED (GB) | 2024-05-02 | — | — | WO | disclosed |
| US-10927068-B2 | Process for preparing acylated amphetamine derivatives | SpecGx LLC (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3717452-A1 | PROCESS FOR PREPARING ACYLATED AMPHETAMINE DERIVATIVES | SpecGx LLC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20190161435-A1 | PROCESS FOR PREPARING ACYLATED AMPHETAMINE DERIVATIVES | SpecGx LLC | 2019-05-30 | — | — | US | disclosed |
| CN-101426496-A | Use of cholesterol lowering agents and/or H3Treatment of non-alcoholic fatty liver disease with receptor antagonists/inverse agonists | SCHERING CORP (US) | 2009-05-06 | — | — | CN | disclosed |
| EP-1442006-B1 | PREPARATION OF AMPHETAMINES FROM PHENYLPROPANOLAMINES | BOEHRINGER INGELHEIM CHEMICALS (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6399828-B1 | ACYLATION OF PHENYLPROPANOLAMINE; CATALYTIC HYDROGENATION | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-4203986-A | TRANQUILIZERS, SEDATIVES, ANTITUSSIVE AGNETS | METABIO-JOULLIE (FR) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927068-B2 | Process for preparing acylated amphetamine derivatives | COMT, DOT1L, AASDHPPT | SLC6A2 169/4885SLC6A3 66/4885TAAR1 483/4885 |
| US-20250368601-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE | PHYKPL, DLST, COMT | SLC6A2 63/4885SLC6A3 19/4885TAAR1 786/4885 |
| US-20190161435-A1 | PROCESS FOR PREPARING ACYLATED AMPHETAMINE DERIVATIVES | COMT, DOT1L, AASDHPPT | SLC6A2 169/4885SLC6A3 66/4885TAAR1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.